In two phase 1 dose-escalation trials (148 enrolled: healthy volunteers and adults with mild asthma and raised FeNO), inhaled elarekibep vs placebo raised no safety concerns; adverse events 35.2% vs 33.3% (single dose) and 75.9% vs 95.5% (multiple dose).
RCTn = 148
Bruns et al. Elarekibep, an inhaled Anticalin protein, targets IL-4Rα locally: first-in-human randomized phase 1 trials of a novel potential therapeutic class in asthma